ライフサイエンスコーパス: metoclopramide

1 All patients had access to paracetamol and metoclopramide.

2 ergics reduce the incidence of PONV, whereas metoclopramide 10 mg does not appear to be effective for

3 ed at these times, we later treated her with metoclopramide (10 mg orally 3 times daily), a medicatio

4 6 attacks with aspirin, 800 to 1000 mg, plus metoclopramide, 10 mg, and patients with MIDAS grade III

5 tment was with aspirin, 800 to 1000 mg, plus metoclopramide, 10 mg.

6 tacks was with aspirin, 800 to 1000 mg, plus metoclopramide, 20 mg.

7 ence and presence of a pharmacologic dose of metoclopramide (3 mg/kg), with or without P-gp inhibitio

8 Metoclopramide, a drug frequently used for nausea and vo

9 ne RCT (n = 159) found no difference between metoclopramide and promethazine after 24 hours (episodes

10 mg/kg per dose over 3 days with concomitant metoclopramide and pyridoxine.

11 Using metoclopramide as a model of CNS drug, we demonstrated t

12 (11)C-metoclopramide benefits from favorable pharmacokinetic p

13 ion, P-gp inhibition significantly increased metoclopramide brain distribution (VT = 6.28 +/- 0.48 mL

14 The (11)C-metoclopramide brain distribution (VT based on Logan plo

15 macologic dose did not affect baseline (11)C-metoclopramide brain kinetics (VT = 2.28 +/- 0.32 and 2.

16 Previous data suggest that metoclopramide brain kinetics may nonetheless be control

17 (11)C-metoclopramide brain kinetics were compared using PET in

18 th two typical neuroleptics, haloperidol and metoclopramide, but not with the atypical neuroleptic cl

19 In this situation, only parent (11)C-metoclopramide could be detected in the brains of P-gp-i

20 gents effective in pseudoobstruction include metoclopramide, domperidone, cisapride, octreotide, and

21 In addition, sulpiride and metoclopramide, drugs with high affinity for D2-dopamine

22 From a cohort of 1,222,503 pregnancies, metoclopramide-exposed and unexposed women were matched

23 3.5 {95% CI, 2.9-4.1} per 1000] among 40,306 metoclopramide-exposed women and 634 cases [3.9 {95% CI,

24 0 {95% CI, 18.5-21.4} per 1000] among 37,946 metoclopramide-exposed women and 9414 cases [62.1 {95% C

25 he kinetic impact of transporter function on metoclopramide exposure to the brain.

26 ted that ginger, vitamin B6, antihistamines, metoclopramide (for mild symptoms), pyridoxine-doxylamin

27 50 = 103 pM) and by the non-selective agents metoclopramide (IC50 = 69 nM), cocaine (IC50 = 459 nM) a

28 Among 28,486 women exposed to metoclopramide in the first trimester, 721 had an infant

29 ticosteroids with placebo or promethazine or metoclopramide in women with severe symptoms.

30 p inform decision making when treatment with metoclopramide is considered in pregnancy.

31 iated with lower nausea scores on day 4 than metoclopramide (mean visual analog scale [VAS] score, 4.

32 The effects of metoclopramide on the central nervous system (CNS) in pa

33 D, 2.9] for ondansetron vs 5.7 [SD, 2.3] for metoclopramide [P = .023]) but not episodes of emesis (5

34 We used (11)C-metoclopramide PET imaging to elucidate the kinetic impa

35 observation, a pilot study was undertaken of metoclopramide therapy in patients with Diamond-Blackfan

36 (11)C-metoclopramide transport by P-glycoprotein (P-gp; ABCB1)

37 (11)C-metoclopramide transport was selective for P-gp over BCR

38 ere were no significant associations between metoclopramide use and malformations overall (prevalence

39 Metoclopramide use in pregnancy was not associated with

40 ours (episodes of vomiting, 1 [IQR, 0-5] for metoclopramide vs 2 [IQR, 0-3] for promethazine [P = .81

41 uidar significantly enhanced microdose (11)C-metoclopramide VT (7.80 +/- 1.43 mLcm(-3)) with a 4.4-fo

42 Metoclopramide was not associated with increased risk of

43 ficant difference between corticosteroids vs metoclopramide was reported (emesis reduction, 40.9% vs

44 ncy, ginger, pyridoxine, antihistamines, and metoclopramide were associated with greater benefit than

45 ms, pyridoxine-doxylamine, promethazine, and metoclopramide were associated with greater benefit than

46 gs tested, but not by chronic treatment with metoclopramide, which has low antipsychotic efficacy but